Findings from the phase 3 MATTERHORN trial supported the FDA approval of perioperative durvalumab for resectable gastric and GEJ cancers.

In this meta-analysis, researchers evaluated the use and/or prolongation of ADT in men with non-metastatic prostate cancer undergoing definitive radiotherapy.

(HealthDay News) — Myelodysplastic syndrome (MDS) is independently associated with incident cardiovascular disease (CVD), according to a study published online Nov. 10 in the Canadian Journal of ...

In this study, researchers evaluated the dose-response relationship between body mass index and the risk of developing pancreatic cancer by the age of 50 years.

In this systematic review, researchers examined the clinical features, diagnosis, treatment, and prognosis of pregnancy-associated colorectal cancer.

In this retrospective analysis, researchers aimed to evaluate outcomes of continuing next-generation ALK TKIs plus chemotherapy after progression on TKI monotherapy in patients with ALK-positive NSCLC ...

In this study, researchers estimated results for 100% lung cancer screening uptake by all unscreened but screening-eligible individuals.

In the phase 3 HER2CLIMB-02 trial, researchers evaluated the efficacy and safety of tucatinib plus T-DM1 compared to T-DM1 alone in HER2+ locally advanced or metastatic breast cancer.

Status quo of choice between colonoscopy and FIT was cost-effective for White adults; CTC was cost-saving versus no screening.

In patients naïve to HER2-targeted therapy, the objective response rate was 71% with a median duration of response of 9.2 months.

Investigators assessed PSA response to treatment at various time points for their relative abilities to predict disease progression in patients with metastatic hormone-sensitive prostate cancer (mHSPC ...

In the study, researchers evaluated county-level data across Pennsylvania for variables such as melanoma incidence, agricultural land use, agrochemical-treated acreage, ambient ultraviolet radiation, ...